FHIR © HL7.org  |  Server Home  |  XIG Home  |  XIG Stats  |  Server Source  |  FHIR  

FHIR IG Statistics: ValueSet/2.16.840.1.113762.1.4.1116.560

Packageus.nlm.vsac
Resource TypeValueSet
Id2.16.840.1.113762.1.4.1116.560
FHIR VersionR4
Sourcehttp://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1116.560/expansion
URLhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.560
Version20240703
Statusactive
Date2024-07-03T01:06:58-04:00
NameRolapitantOral
TitleRolapitant Oral
Realmus
Authorityhl7
Purpose(Clinical Focus: The purpose of this value set is to represent concepts of medication Rolapitant.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication Rolapitant; generic; prescribable; oral.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)

Resources that use this resource

ValueSet
2.16.840.1.113762.1.4.1116.602Neurokinin 1 Receptor Antagonist
2.16.840.1.113883.3.1444.5.245Antiemetic Agent

Resources that this resource uses

CodeSystem
rxnormRxNorm

Narrative

No narrative content found in resource


Source

{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1116.560",
  "meta": {
    "versionId": "16",
    "lastUpdated": "2024-07-03T01:06:58.000-04:00",
    "profile": [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueContactDetail": {
        "name": "American Society of Clinical Oncology Author"
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate": "2025-04-08"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate": "2024-07-03"
    }
  ],
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.560",
  "identifier": [
    {
      "system": "urn:ietf:rfc:3986",
      "value": "urn:oid:2.16.840.1.113762.1.4.1116.560"
    }
  ],
  "version": "20240703",
  "name": "RolapitantOral",
  "title": "Rolapitant Oral",
  "status": "active",
  "date": "2024-07-03T01:06:58-04:00",
  "publisher": "American Society of Clinical Oncology Steward",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "urn:iso:std:iso:3166",
          "code": "US"
        }
      ]
    }
  ],
  "purpose": "(Clinical Focus: The purpose of this value set is to represent concepts of medication Rolapitant.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication Rolapitant; generic; prescribable; oral.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)",
  "compose": {
    "include": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "concept": [
          {
            "code": "1665503",
            "display": "rolapitant 90 MG Oral Tablet"
          }
        ]
      }
    ]
  },
  "expansion": {
    "identifier": "urn:uuid:543ad95e-876d-4f2c-8716-c22d895f50e5",
    "timestamp": "2025-05-23T18:19:26-04:00",
    "total": 1,
    "contains": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1665503",
        "display": "rolapitant 90 MG Oral Tablet"
      }
    ]
  }
}